Pyxis Oncology Inc. (PYXS): Utang marang Ekuitas

Logo korporat perusahaan Pyxis Oncology (PYXS)

This chart illustrates that Pyxis Oncology, Inc. (PYXS) maintains a debt-to-equity ratio of 1.54, while the business relies on precise biopharmaceutical transportation to preserve margins through its laboratory network. Amidst fierce patent battles with pharma behemoths, the company risks facing scientific setbacks. Pipeline development is based on targeted licensing and research alliances to validate new molecules.

PYXS: Rasio Total Utang marang Ekuitas Pyxis 04.07.2022 - 30.10.2026

Rincian metrik komprehensif lan analitis Pyxis Oncology (PYXS)

- rega lan prakiraan konsensus rega:
Bagan rega Pyxis Oncology Inc.|PYXS - Rata-rata rega prakiraan
- data kapitalisasi bursa:
Nilai pasar Pyxis Oncology|PYXS - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham Pyxis Oncology|PYXS - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku pyxisoncology.com|PYXS - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Pyxis Oncology, Inc.|PYXS - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Pyxis Oncology Inc.|PYXS - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Pyxis Oncology|PYXS - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Pyxis Oncology|Indikator likuiditas cepet pyxisoncology.com
- informasi bathi lan kelipatan valuasi:
PYXS - Bathi pungkasan
Analisis fundamental perusahaan:Pyxis Oncology, Inc., PYXS
Barang utama Pyxis Oncology Inc.

Pyxis Oncology, Inc. (PYXS) demonstrates resilience through the development of innovative drugs that remain independent of global macroeconomic fluctuations. An analysis of the total debt-to-equity ratio allows for an assessment of the proportion of borrowed funds relative to the issuer's own assets. This metric measures financial leverage, determining the extent of the business's dependence on external creditors. A low leverage level confirms the company's high degree of autonomy. Such a balance sheet structure guarantees the reliability of investments in the defensive medical sector.

Pesaing Pyxis Oncology, Inc. (PYXS)

Utang marang Ekuitas ImmunityBio|Utang marang Modal Immunocore Holdings IMCR|Utang marang Ekuitas Janux Pharma (JANX)|Arcus Corp - Rasio Utang marang Ekuitas|Total Utang marang Modal ZYME (Zymeworks Inc.)|TNGX - Rasio Total Utang marang Ekuitas|IOVA - Utang marang Ekuitas|Utang marang Modal Immatics NV|Xencor Corp (XNCR) - Utang marang Ekuitas|CMPX (Compass Therapeutics Corp) - Utang marang Ekuitas|Utang marang Ekuitas Replimune Group, Inc.|Utang marang Modal lyell.com LYEL|Total Utang marang Modal IPHA|cgen.com (CGEN) - Rasio Utang marang Modal|IO Biotech Corp - Rasio Total Utang marang Ekuitas|Sutro Biopharma, Inc (STRO) - Utang marang Modal|INKT: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi HOWL (Werewolf Therapeutics)|IMMX: Total Utang marang Modal|ALXO - Koefisien Total Utang marang Modal|Utang marang Ekuitas Cue Biopharma, Inc.|Rasio Total Utang marang Ekuitas PDS Biotechnology Corp (PDSB)|Utang marang Ekuitas Sonnet BioTherapeutics (SONN)|Rasio Total Utang marang Ekuitas MAIABiotech.com MAIA|Liminatus Pharma LLC - Rasio Total Utang marang Ekuitas|Total Utang marang Modal LAVA Therapeutics NV LVTX|NXTC - Utang marang Ekuitas|LPTX (Leap Therapeutics, Inc.) - Rasio Utang marang Ekuitas|intensitytherapeutics.com (INTS) - Utang marang Ekuitas|Utang marang Modal Sensei Biotherapeutics, Inc. (SNSE)|Rasio Total Utang marang Ekuitas TOVX|GRTS - Rasio Utang marang Modal|Rasio Total Utang marang Ekuitas KA (Kineta Bio)|Utang Agregat marang Modal NEXI|Total Utang marang Modal TSBX (Turnstone Biologics Corp.)|Rasio Kabeh Utang marang Dana Pribadi VCNX|Harpoon Therapeutics, Inc. - Total Utang marang Modal